Last reviewed · How we verify
NCT03262259: GSDG
Evaluation of Global Smart Drinking Goals Initiative
NA trial testing GSDG multi-component intervention in Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms in 36,000 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | HBSA |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 36,000 |
| Start date | 1 September 2017 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- GSDG multi-component intervention
Conditions studied
- Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms — all drugs for Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms →
Sponsor
HBSA
Who can join
12 and older, any sex, with Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate effects of a multi-component, population-level intervention on alcohol use and related harms in six intervention cities relative to six matched comparison cities. Intervention components include screening and brief interventions by health providers, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation. Key outcomes of interest include alcohol-related harms such as alcohol-related motor vehicle crashes and fatalities, heavy/binge drinking, underage drinking, and drinking and driving.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Design and outcome measures for the AB InBev Global Smart Drinking Goals evaluation.
Miller TR, Ringwalt CL, Grube JW, Paschall MJ, et al · · 2019 · cited 5× · PMID 31650076 · DOI 10.1016/j.conctc.2019.100458
Verify or expand the search:
- PubMed search for NCT03262259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other HBSA trials
Trials by the same sponsor.
- NCT04699526 — Evaluation of Universal Prevention Curriculum for Schools in Peru · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03262259 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HBSA
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03262259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing